Tempus AI, Inc. Q3 2026 Earnings Call Summary
Tempus AI reported Q3 2026 earnings, highlighting 32% oncology unit growth and 33% momentum in Data and Applications. The company achieved $25.6M in adjusted EBITDA, with full-year revenue guidance raised to $1.6B. Strategic collaborations with BMS, Moderna, and Merck were noted, along with a pending acquisition of Personalis for $20B MRD market positioning. Management targets 25% long-term revenue CAGR and expects $65M adjusted EBITDA for 2026.
How this was made
The 30-second read
Why it matters
The earnings call delivers fresh financial data and strategic milestones, offering traders a basis for short‑term positioning and longer‑term valuation adjustments.
Market read
The new guidance and acquisition clearance could drive a rally in TPUS and positively affect related precision‑medicine stocks.
What to watch
Regulatory risk around MRD assay approvals and the scalability of the Lens data platform could temper upside.
Background
Tempus AI is a precision‑medicine company that combines genomic testing with AI‑driven data platforms. The Q3 2026 earnings call provided the first public disclosure of its updated guidance and acquisition status.
Market effects
Higher guidance may lift other precision‑medicine and data‑analytics stocks as the market reassesses growth potential in oncology and AI‑driven diagnostics.
U.S. biotech and health‑tech sector could see modest gains.
The Personalis acquisition signals consolidation in the global MRD market, potentially influencing international competitors.
Counterpoint
If the integration of Personalis faces delays or reimbursement hurdles, the guidance uplift may be overstated.
Key entities
- companyTempus AI, Inc.
Subject of the earnings call and guidance update.
- companyPersonalis
Acquisition target whose deal cleared regulatory review.
